Neuromyelitis Optica (NMO) FAQ
Neuromyelitis Optica (NMO) FAQ
This page answers the questions that decide whether anything happens next: what an assessment costs and what drives that figure, how long a stay involves and why the answer splits depending on whether the person needs to be here at all, what to send first and why the sequence and the regions imaged matter more than the summary, when travelling is worth it and when it is not , how insurance is handled and the two checks worth making in advance, what comes home in writing, and why a companion matters more here than in most conditions. The order is deliberate: the answer about whether travelling would change anything comes before the costs, because it is the one that should be said first.
What it costs, and what drives the figure
An assessment is a clinic visit or a short admission, and the figure is driven by what the question requires rather than by how unwell the person looks. Families expect the cost to track severity; it does not. It tracks the number of open questions.
Three things move it. The assessment itself — records reviewed, imaging reviewed, a plan written — sits at the lower end. The items added because a question was raised rather than as a package: the aquaporin-4 and MOG antibody tests with the assay specified, a repeat scan of the cord with contrast, imaging of the orbits, or a repeat of the spinal fluid. And treatment, where that becomes part of the plan rather than assessment alone, which is a separate figure and a separate conversation. Fully treated costs typically run at 30–50% of comparable care in Europe or the United States. That is a range rather than a quote, and what places an individual case within it is what the assessment contains.
What should happen, and is worth asking for anywhere, is that a written plan with its costs is given before anything is arranged, with the optional parts stated as optional. An estimate that arrives after a workup has begun is not an estimate; it is a bill in waiting. Where a medicine or procedure recommended is not carried out within this pathway, that is named at the outset, before any payment is discussed.
How long a stay involves
This is the question whose answer splits in two, and it is worth saying which half applies before anyone books anything.
Assessment, from records alone. A written opinion is returned within 48 hours of complete records arriving — from the point the file is complete rather than the point it is first sent. For many families this is the right first step, because it answers whether travelling is worth it before anyone travels, and in this condition it frequently answers the question outright: the commonest finding is that the antibody test was never sent.
Assessment, with the person here. Where the question requires examination, imaging or a repeat of the fluid, a stay covers the assessment, whatever is indicated, and the review at which the plan is given. What determines the length is which of those three is needed, and that is decided before rather than during the stay.
Treatment. Where treatment is part of the plan, it is a separate length and a separate figure, discussed as it sits in this pathway: what it involves, what monitoring it requires, and what it commits a person to afterwards — which in this condition is measured in years rather than in days.
What to send first
Four items, in the order of how much they change the answer.
The imaging with its reports, in date order — the images rather than a description of them, and the cord and the orbits as well as the brain. Whether the cord was imaged at all is often the decisive fact in the file, and a report that describes a cord lesion without saying how many segments it spans has left out the finding that matters. A scan without its previous one beside it cannot answer whether anything is new.
Any spinal fluid result, with its date, including whether the oligoclonal bands were paired against a blood sample drawn at the same time. In this condition the bands are absent in most people, which makes the result useful in both directions — and it is the item most often missing from a summary.
The list of antibody tests that were performed, with the assay named — the aquaporin-4 and MOG antibodies most of all. A file that says demyelinating disease without either result is a file in which a different disease with a different treatment has not been excluded, and it is the single most useful thing to check before travelling anywhere.
A short account in your own words of each attack in the order it happened: what arrived, how fast, and what went away again. Alongside it, note what has quietly changed between attacks — energy, heat tolerance, vision, bladder. That account is the single most informative thing a family can supply, and the one most often replaced by a list of diagnoses.
When travelling is worth it, and when it is not
Four situations justify the journey, and one does not.
Worth it. A myelitis or an optic neuritis that was treated and discharged with no one having said which condition it belonged to, and no antibody test ever sent. A diagnosis of multiple sclerosis made without the antibody tests — which matters more here than anywhere, because several of the medicines used for multiple sclerosis worsen this condition. A cord lesion described as long, in a report that never says how long. And the half that no scan shows — spasticity, pain, bladder function and fatigue — that has reorganised a working life and never been formally assessed.
Not worth it. Where a plan is already running well locally and nothing here would change it, or where the honest answer is that no further test would alter what is done. That is said as plainly as the alternative and is not converted into an itinerary.
The one point that should be made first, and is: send the records before booking anything. The commonest outcome of a records review here is that the question is answered without a journey at all — usually by identifying the one test that was never sent.
Insurance, and the two checks worth making
More than 30 commercial insurers are billed directly, and we will tell you whether yours is among them before you travel rather than after.
Two checks are worth making in advance, and both are specific to this condition. The first is whether the policy covers assessment rather than only treatment — a workup that concludes nothing was found is still a workup, and that is exactly where many families are. The second is whether it covers ongoing maintenance therapy and its monitoring, because a regimen measured in years, with blood tests and imaging attached, is a different claim from an admission measured in days. Discovering that at month six is discovering it at the wrong end.
Where neither is covered, the written plan with its costs — given before anything is arranged — is what makes the decision possible. And where the plan involves a medicine that is not carried out within this pathway, that is named at the outset rather than at the end of a workup.
What comes home with you
Five things in writing, and a family is entitled to ask for each of them.
First, the antibody result, naming the assay and the specimen — which antibody, on serum or fluid, by what method. Second, which regions were imaged, so that a reader can tell whether the cord was included, whether the orbits were imaged, and whether contrast was given. Third, which alternatives have been excluded and on what grounds, naming multiple sclerosis and MOG antibody disease specifically — because a differential that was considered but not tested is not an exclusion. Fourth, what would change the answer, including whether a repeat antibody during a relapse is the right next step. Fifth, what the follow-up has to contain: how often imaging is repeated and why, which symptoms are asked about at each visit by name, and what finding would prompt a change in treatment.
That last item is the one that changes a life most, and the one most often left out. A review built around whether a new lesion has appeared will not surface spasticity, pain, bladder function, fatigue or mood. A review that lists them as items will.
Bringing someone with you
It matters more here than in most conditions, for two reasons.
The first is that the most informative part of the file is a chronological account, and the person who has it is frequently not the patient. What arrived first, how fast it came on, whether it went away and how completely, and what has quietly changed in between — a companion often holds that more accurately than someone who has been living inside it and has stopped noticing the increments.
The second is that much of what is discussed is a plan rather than a result: intervals, monitoring requirements, what would change the treatment, what to watch for. Two people hear a plan better than one, and the companion is usually the one who remembers to ask the question that otherwise gets left until the car park. For the half no scan shows in particular — spasticity, pain, bladder, fatigue — having someone who can say what a week actually looks like is the difference between it being noted and being missed.